Thrombopoietin: A novel candidate tumor marker for the diagnosis of ovarian cancer

Journal of Gynecologic Oncology

Volumn 23, Issue 2, 2012, Pages 86-90

  Mermer, Timucin ^a   Terek, Mustafa Cosan ^a   Zeybek, Burak ^a   Ergenoglu, Ahmet Mete ^a   Yeniel, Ahmet Ozgur ^a   Ozsaran, Aydin ^a   Zekioglu, Osman ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Biological tumor markers; Ovarian neoplasms; Thrombopoietin

Indexed keywords

CA 125 ANTIGEN; THROMBOPOIETIN; TUMOR MARKER;

ADNEXA DISEASE; ADULT; ARTICLE; ASCITES; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CYTOLOGY; DISEASE SEVERITY; FEMALE; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MENOPAUSE; OVARY CANCER; POSTOPERATIVE CARE; PREDICTIVE VALUE; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84859141114     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2012.23.2.86     Document Type: Article

References (16)

1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-27.
2. Ries LA, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER cancer statistics review, 1975-2003. Bethesda, MD: National Cancer Institute; 2005.
3. Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynaecol 1998;105:1136-47.
4. Markman M. The role of CA-125 in the management of ovarian cancer. Oncologist 1997;2:6-9.
5. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193:1630-9.
6. Rapkiewicz AV, Espina V, Petricoin EF 3rd, Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer 2004;40:2604-12.
7. Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, Hensley ML, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004;22:3330-9.
8. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369: 533-8.
9. Furuhashi M, Miyabe Y, Oda H. A case of thrombopoietinproducing ovarian carcinoma confirmed by immunohistochemistry. Gynecol Oncol 1999;74:278-81.
10. Komura E, Matsumura T, Kato T, Tahara T, Tsunoda Y, Sawada T. Thrombopoietin in patients with hepatoblastoma. Stem Cells 1998;16:329-33.
11. Ryu T, Nishimura S, Miura H, Yamada H, Morita H, Miyazaki H, et al. Thrombopoietin-producing hepatocellular carcinoma. Intern Med 2003;42:730-4.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
13. Torres MP, Ponnusamy MP, Lakshmanan I, Batra SK. Immunopathogenesis of ovarian cancer. Minerva Med 2009;100:385-400.
14. Chambers SK. Role of CSF-1 in progression of epithelial ovarian cancer. Future Oncol 2009;5:1429-40.
15. Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, et al. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 2010;31:375-83.
16. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts. Eur J Obstet Gynecol Reprod Biol 2008;140:67-70.